EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 145 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... June 24, 2019 Can’t Sleep? Tips for Coping with Insomnia August 4, 2021 Load more HOT NEWS Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 Teacher Is Glad She Asked for More Testing After Mammogram Failed... Mom Wants Disney To Ban Childless Adults From Their Theme Parks Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis...
